1 / 27

Infertility Prevention Project Advisory Committee | May 16-17, 2007

The presentation covers topics such as budget updates, ongoing projects, performance measures activities, and CSPS updates for Infertility Prevention Project. Includes information on azithromycin pricing, IPP, and program management.

hberg
Download Presentation

Infertility Prevention Project Advisory Committee | May 16-17, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Region II Infertility Prevention Project Advisory CommitteeMay 16-17, 2007New York, New York Steven J. Shapiro Infertility Prevention Project Coordinator CDC/NCHHSTP/DSTDP/PTB (proposed) Disclaimer: The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  2. Topics • Budget Update • CSPS Update • Ongoing Projects • Performance Measures Activities • Performance Measures Data

  3. Budget 2007 • Flat Funding for STD Prevention • Funded at Final 2006 levels • Approx. $107 million to grantees • Infrastructure Funding • Base Award • Special Project • STD Conference Travel Funds • Data Systems Standardization

  4. CSPS 2008 • CSPS 2008 • Continuation Application Due August 17, 2008 • Program plans, reflective of regional activities, must be developed with FP and Lab • FP concurrence letter • CSPS Background, IPP plan and budget must be made available to the regional coordinator with enough time for inclusion of feedback into application • At least 50% used to support screening and treatment in FP partner facilities • Local prevalence monitoring data should be used to allocate resources • Application must include objectives related to the IPP Performance Measures

  5. CSPS 2009 • CSPS 2009 • 5 year Cooperative Agreement • Possible increased flexibility in using awarded IPP funds • Integration Language • Better matching of CSPS and Infrastructure • Need for regional screening criteria • Emphasis on completing required IPP activities • Ensure CT and GC screening and treatment • Support laboratory testing • Ensure collection of all CDC core data elements • Program Management • Provider Training

  6. Ongoing Projects • Azithromycin Pricing • Infertility Prevention Workgroup • Performance Measures • CSPS • Infrastructure

  7. Azithromycin • Off Patent 2006 • Contract (Pfizer) Sub-ceiling 340B pricing of $95 per 10 doses of 1 gm sachet not longer valid • Available in various formulations and dosages from three manufacturers and numerous distributors nationwide • Region II • STD Programs $2.10-$15.52/dose • FP Programs $2.24-$10.26/dose • National Range $0.38 - $24.50/dose

  8. Infertility Prevention Workgroup • Summary of IPW Submission: • Common theme: • Should the Division support increased screening of females under the age of 26 for Ct in public and private sectors? • Supporting Priorities • Social Marketing • Monitoring of Screening Coverage • Current Activities • Blueprint Development • Staffing Plan

  9. Performance Measures Activities • NCSD Consultation (January 2006) • Expansion of CSPS Performance Measures • Timeliness Treatment STD clinics • Gender of sex partner infectious syphilis • Infrastructure Performance Measures • Screening Coverage • Proportion of tests by age • NCSD Consultation (February 2007) • Re-infection • Hepatitis B Vaccination in STD Clinics • Cost of partner services interventions • Congenital Syphilis • Performance Measures Learning Tours

  10. Questions?

  11. Performance MeasuresData Review • Region II and National Summary Data • Data Verification • Prevalence Monitoring and Performance Measure Data • Regional Summary • Project Area Snapshot

  12. Performance MeasureIPP CS1 Among clients of IPP Family Planning clinics, the proportion of women with positive chlamydia tests treated within 14 and 30 days of the date of specimen collection.

  13. IPP CS 1 (Chlamydia) Results

  14. Performance MeasureIPP CS2 Among clients of IPP Family Planning clinics, the proportion of women with positive gonorhea tests treated within 14 and 30 days of the date of specimen collection.

  15. IPP CS 2 (Gonorrhea) Results

  16. Performance MeasureCSPS MLS1 Proportion of female admittees to large juvenile detention centers tested for chlamydia.

  17. CSPS MLS1 (JDC Screening) Results

  18. Data Verification • Performance Measures Guidance: • IPP Family Planning Clinics: All family planning clinics that report data as part of the Chlamydia Prevalence Monitoring Project, regardless of whether they are integrated clinics or not. • Denominator: Total number of women who tested positive for chlamydia (at those family planning clinics) • In other words: If ten FP clinics in a jurisdiction report 500 CT positives and 9500 CT negatives to the prevalence monitoring database, then the denominator for the performance measure should be 500.

  19. Prevalence Monitoring v. Performance MeasureFemales in IPP Family Planning ClinicsChlamydia and Gonorrhea 2005Region II Summary

  20. Reasons for Differences • 2005 data • If Prev. Monitoring > Perf. Measures • Prevalence Monitoring data includes only those clinics who reported more than a total of 25 tests during the year • Not counting integrated clinics • If Prev. Monitoring < Perf. Measures • Non-prevalence monitoring FP sites submitting data for performance measures • Counting non-FP sites • ???

  21. Prevalence Monitoring v. Performance MeasureFemales in IPP Family Planning ClinicsChlamydia 2005

  22. Prevalence Monitoring v. Performance MeasureFemales in IPP Family Planning ClinicsGonorrhea 2005

  23. Questions?

More Related